|
WO2021081026A1
|
|
Complement component c3 irna compositions and methods of use thereof
|
|
WO2021076828A1
|
|
Solute carrier family member irna compositions and methods of use thereof
|
|
WO2021072395A1
|
|
Modified oligonucleotides
|
|
WO2021067747A1
|
|
Compositions and methods for silencing ugt1a1 gene expression
|
|
WO2021046122A1
|
|
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2021041884A1
|
|
Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
|
|
WO2021030522A1
|
|
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021022109A1
|
|
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021022108A2
|
|
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2020257483A1
|
|
Structurally defined sirna-dual variable domain immunoglobulin conjugates
|
|
WO2020257194A1
|
|
Delivery of oligonucleotides to the striatum
|
|
WO2020236600A1
|
|
Oral delivery of oligonucleotides
|
|
WO2020132227A2
|
|
AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2020097044A1
|
|
Modified double stranded oligonucleotides
|
|
CA3114435A1
|
|
Biodegradable lipids for the delivery of active agents
|
|
CA3114396A1
|
|
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
WO2020060987A1
|
|
Complement component c5 irna compositions and methods of use
|
|
CA3105385A1
|
|
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
WO2020037125A1
|
|
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2020036862A1
|
|
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
